Brokers Issue Forecasts for TARS Q1 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Tarsus Pharmaceuticals in a research report issued on Wednesday, February 26th. HC Wainwright analyst O. Livnat expects that the company will earn ($0.80) per share for the quarter. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.59) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at $1.52 EPS, FY2026 earnings at $1.52 EPS, FY2027 earnings at $4.14 EPS and FY2027 earnings at $4.14 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million.

A number of other research firms have also recently commented on TARS. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Guggenheim reaffirmed a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays cut their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Stock Up 2.1 %

NASDAQ:TARS opened at $44.48 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The stock’s fifty day moving average is $50.97 and its two-hundred day moving average is $43.13. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -11.67 and a beta of 1.01.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares during the last quarter. Creative Planning purchased a new position in Tarsus Pharmaceuticals in the third quarter valued at $362,000. Vestal Point Capital LP purchased a new position in Tarsus Pharmaceuticals in the third quarter valued at $7,565,000. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after buying an additional 321,552 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new position in Tarsus Pharmaceuticals in the third quarter valued at $763,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.